Best Small-Cap Stocks to Watch Q2 2026
The 10 highest-scoring small-cap stocks entering Q2 2026, ranked by our 8-metric fundamental model. Start your free 30-day trial today.
As Q2 2026 begins, identifying the best small-cap stocks requires cutting through a universe of 2,200+ names to find the handful with genuinely strong fundamentals. Right now, only 47 of those names carry a fundamental score above 80/100 — roughly 2% of everything we track. That narrow slice represents the strongest combination of growth, profitability, and financial health available in the small-cap market today.
Here are the 10 highest-scoring stocks entering the quarter, along with the data behind each.
The Macro Context for Q2 2026
Before diving into individual names, it's worth framing the environment these companies are operating in.
Small-cap stocks as a category have historically outperformed large-caps over long time horizons, but with meaningfully higher volatility. The Russell 2000, the primary benchmark for U.S. small-cap equities, is more sensitive to domestic economic conditions than large-cap indices — which means interest rate trajectory, credit availability, and consumer spending all carry outsized influence on this segment.
Entering Q2 2026, the macro backdrop presents both tailwinds and headwinds:
- Interest rates: Elevated-but-declining rates continue to pressure growth-oriented small-caps with negative earnings, while rewarding profitable companies. The names on this list are disproportionately profitable — that's not an accident.
- Defense and aerospace spending: Multi-year budget commitments are translating into durable revenue for industrials suppliers. Carpenter Technology (CRS) is a direct example.
- Pharmaceutical consolidation: Large-cap pharma continues to acquire smaller biotech and specialty pharma names to replenish pipelines. Several companies on this list operate in spaces that make them realistic acquisition targets.
- Semiconductor infrastructure: CHIPS Act disbursements are moving from legislation to active construction, benefiting equipment suppliers like Axcelis Technologies.
None of these macro factors override the fundamentals. They provide context for why certain businesses are growing — and which tailwinds have durability.
How We Selected These Stocks
Every stock below was selected purely by its fundamental score — an 8-metric composite that measures revenue growth, gross margins, cash runway, valuation, balance sheet strength, insider ownership, capital discipline, and the Rule of 40.
No discretionary overrides. No "gut feeling." Just data.
The eight metrics are weighted to reward both growth and financial discipline simultaneously. A company growing 50% but burning through cash at an unsustainable rate will score lower than a company growing 20% with a clean balance sheet. Valuation is included as a check against overpaying for quality — a 91/100 business trading at 30x sales scores differently than the same business at 5x sales.
For a full breakdown of how each metric is weighted and calculated, see our how it works page. If you want to understand the individual metrics in more detail, our guide to 8 fundamental metrics for small-cap investors covers each one.
Important: This is a pre-filter, not a buy list. Each stock warrants additional research before any investment decision. Scores reflect the most recent quarterly data available. Always verify current figures directly in company filings on SEC EDGAR before acting on any analysis.
The Top 10 for Q2 2026
1. Corcept Therapeutics (CORT) — Score: 91/100
| Metric | Value |
|---|---|
| Revenue Growth | +38% YoY |
| Gross Margin | 78% |
| P/S Ratio | 8.2x |
| Debt/Equity | 0% |
| Cash Runway | Profitable |
| Insider Ownership | 7.8% |
Corcept continues to dominate the cortisol modulation space with its lead drug Korlym. The company is debt-free, highly profitable, and growing revenue at nearly 40% annually. The premium valuation (8.2x sales) is the only metric holding the score back from a perfect 100.
Key catalyst: Phase 3 data for relacorilant, which could significantly expand the addressable market beyond Cushing's syndrome.
Risk: Single-product concentration. If relacorilant fails or Korlym faces generic competition, the growth story changes materially.
2. Catalyst Pharmaceuticals (CPRX) — Score: 89/100
| Metric | Value |
|---|---|
| Revenue Growth | +22% YoY |
| Gross Margin | 91% |
| P/S Ratio | 5.4x |
| Debt/Equity | 0% |
| Cash Runway | Profitable |
| Insider Ownership | 4.2% |
A 91% gross margin is extraordinary by any standard. Catalyst's rare disease drug Firdapse generates consistent, high-margin revenue with limited competition. The company carries zero debt.
Key catalyst: Pipeline expansion into additional rare neurological conditions could diversify the revenue base.
Risk: Rare disease market size is inherently limited. Growth depends on geographic expansion and new indications.
3. Supernus Pharmaceuticals (SUPN) — Score: 87/100
| Metric | Value |
|---|---|
| Revenue Growth | +15% YoY |
| Gross Margin | 84% |
| P/S Ratio | 2.1x |
| Debt/Equity | 18% |
| Cash Runway | Profitable |
| Insider Ownership | 5.1% |
Supernus offers a rare combination in biopharma: strong revenue growth, high margins, and a reasonable valuation. At 2.1x sales, it's one of the cheapest profitable specialty pharma companies in our universe.
Key catalyst: Continued adoption of its CNS portfolio, particularly in ADHD and epilepsy treatments.
Risk: Moderate debt and dependence on a narrow therapeutic focus.
4. Pacira BioSciences (PCRX) — Score: 85/100
| Metric | Value |
|---|---|
| Revenue Growth | +9% YoY |
| Gross Margin | 72% |
| P/S Ratio | 1.8x |
| Debt/Equity | 42% |
| Cash Runway | Profitable |
| Insider Ownership | 3.6% |
Pacira's non-opioid pain management portfolio addresses a massive market need. Exparel, its lead product, continues to gain share as hospitals seek alternatives to opioid-based post-surgical pain management.
Key catalyst: Hospital adoption metrics continue trending upward. CMS reimbursement changes could accelerate adoption.
Risk: Higher debt load than peers. Patent expirations in the medium term require pipeline execution.
5. Iovance Biotherapeutics (IOVA) — Score: 84/100
| Metric | Value |
|---|---|
| Revenue Growth | +312% YoY |
| Gross Margin | 58% |
| P/S Ratio | 3.7x |
| Debt/Equity | 15% |
| Cash Runway | 20 months |
| Insider Ownership | 2.8% |
Iovance is the breakout story of the past 12 months. Its TIL therapy Amtagvi received FDA approval, and revenue has ramped from near zero to meaningful commercial sales. The 312% growth rate is among the highest in our entire universe.
Key catalyst: Manufacturing scale-up and additional tumor type approvals could multiply the addressable market.
Risk: Cash runway of 20 months means the company will need the commercial launch to reach profitability — or raise additional capital.
6. Axcelis Technologies (ACLS) — Score: 83/100
| Metric | Value |
|---|---|
| Revenue Growth | +11% YoY |
| Gross Margin | 45% |
| P/S Ratio | 2.8x |
| Debt/Equity | 0% |
| Cash Runway | Profitable |
| Insider Ownership | 3.1% |
Axcelis is a semiconductor equipment company benefiting from the global push to build domestic chip manufacturing capacity. Zero debt and consistent profitability make it one of the most financially sound small-caps in the tech sector.
Key catalyst: CHIPS Act spending continues to flow into new fab construction, driving demand for ion implantation equipment.
Risk: Semiconductor equipment demand is highly cyclical. An industry downturn could compress revenues.
7. Carpenter Technology (CRS) — Score: 82/100
| Metric | Value |
|---|---|
| Revenue Growth | +19% YoY |
| Gross Margin | 28% |
| P/S Ratio | 3.5x |
| Debt/Equity | 35% |
| Cash Runway | Profitable |
| Insider Ownership | 1.9% |
Carpenter Technology manufactures specialty alloys used in aerospace, defense, and medical applications. The company has become a direct beneficiary of increased defense spending and the aerospace production ramp-up.
Key catalyst: Boeing and Airbus production rate increases directly drive demand for Carpenter's high-performance alloys.
Risk: Raw material costs and energy prices can compress margins. Cyclicality in aerospace spending.
8. Cal-Maine Foods (CALM) — Score: 81/100
| Metric | Value |
|---|---|
| Revenue Growth | +65% YoY |
| Gross Margin | 48% |
| P/S Ratio | 0.9x |
| Debt/Equity | 0% |
| Cash Runway | Profitable |
| Insider Ownership | 12.4% |
Cal-Maine is the largest egg producer in the U.S. and has been a major beneficiary of elevated egg prices. At 0.9x sales with zero debt and 12.4% insider ownership, it scores exceptionally well on both valuation and alignment metrics.
Key catalyst: Continued tight supply conditions in the egg market supporting pricing power.
Risk: Egg prices are inherently volatile. A supply normalization could sharply reduce revenue and margins. This is a commodity business.
9. Lantheus Holdings (LNTH) — Score: 80/100
| Metric | Value |
|---|---|
| Revenue Growth | +24% YoY |
| Gross Margin | 64% |
| P/S Ratio | 4.1x |
| Debt/Equity | 22% |
| Cash Runway | Profitable |
| Insider Ownership | 2.3% |
Lantheus dominates the radiopharmaceutical diagnostics space with its PYLARIFY imaging agent for prostate cancer detection. The company has built a strong competitive position in a high-growth niche.
Key catalyst: Expansion into additional radiopharmaceutical indications and potential therapeutic applications.
Risk: PYLARIFY concentration risk. Reimbursement changes or competitive entries could pressure the growth trajectory.
10. Remitly Global (RELY) — Score: 80/100
| Metric | Value |
|---|---|
| Revenue Growth | +33% YoY |
| Gross Margin | 55% |
| P/S Ratio | 4.8x |
| Debt/Equity | 8% |
| Cash Runway | 30+ months |
| Insider Ownership | 6.1% |
Remitly is disrupting the $700 billion global remittance market with its digital-first platform. Strong revenue growth, healthy margins, and low debt position it well for continued market share gains.
Key catalyst: Geographic expansion and increasing digital adoption in remittance corridors.
Risk: Competition from established players (Western Union, Wise) and fintech upstarts. Path to sustained profitability still developing.
Score Distribution Context
To put these scores in perspective:
| Score Range | Number of Stocks | Percentage |
|---|---|---|
| 80–100 | 47 | 2.1% |
| 60–79 | 284 | 12.9% |
| 40–59 | 621 | 28.2% |
| 20–39 | 789 | 35.9% |
| 0–19 | 459 | 20.9% |
Scoring above 80 puts a stock in the top 2% of all small-caps by fundamental quality. That doesn't mean these stocks will outperform — but it does mean the underlying business metrics are exceptionally strong relative to peers.
For context on what "small-cap" means as a category and how these companies compare to mid- and large-cap equities, Investopedia's overview of small-cap stocks is a reliable reference.
What Separates These 10 From the Rest
Looking across the list, a few structural patterns explain why these names rose to the top.
Profitability as a Filter
Nine of the ten companies are currently profitable. In a small-cap universe where the majority of companies are pre-profitability or marginally profitable, this is a meaningful differentiator. Profitable companies with clean balance sheets have the flexibility to invest in growth, return capital to shareholders, or weather a downturn — none of which unprofitable companies can do without diluting existing shareholders.
Low or Zero Debt
Six of the ten carry debt-to-equity ratios below 20%. Four carry zero debt. Small-cap companies with high debt loads are far more vulnerable to rate environments, refinancing risk, and covenant restrictions. The companies on this list have largely avoided that trap.
Insider Alignment
Insider ownership across the list ranges from 1.9% (CRS) to 12.4% (CALM). High insider ownership means management has personal financial skin in the game — a metric that research consistently links to better long-term outcomes for outside shareholders. It also reduces the likelihood of value-destructive acquisitions or excessive compensation at shareholder expense.
If you want to understand how to find stocks with similar profiles before they show up on lists like this, our guide on how to find undervalued small-cap stocks walks through the full process.
How to Use This List
This is a research starting point, not a portfolio. Each stock on this list has strong fundamentals, but the final investment decision should include:
- Reading the latest 10-Q/10-K filings on SEC EDGAR
- Understanding competitive dynamics
- Assessing management quality and capital allocation
- Evaluating your own risk tolerance and portfolio concentration
Explore the full list of high-scoring stocks in our screener, where you can filter by score, sector, and individual metrics. The screener is updated as new quarterly data becomes available — so the rankings shift as companies report.
This article is for informational purposes only and does not constitute financial advice. Past fundamental scores do not guarantee future stock performance. Always conduct your own research before making investment decisions.